

Drug Utilization Review Board

(DUR Board)

Meeting – March 11, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. February 11, 2008 DUR Minutes – Vote
 - B. February 13, 2008 DUR Recommendation Memorandum
 - C. Provider Correspondence

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

4. **Update on DUR / MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review Responses for October 2008
 - B. Medication Coverage Activity Audit for February 2009
 - C. Help Desk Activity Audit for February 2009

Items to be presented by Dr. Le, Dr. McNeill, Chairman

5. **Action Item – Vote to Prior Authorize Advair[®] and Symbicort[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman

6. **Action Item – Vote to Prior Authorize Fenoglide[™], Lipofen[®], and Trilipix[™] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Robinson, Dr. McNeill, Chairman

7. **Action Item – Vote to Prior Authorize Astepro[®] – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Robinson, Dr. McNeill, Chairman

8. **Action Item – Annual Review of Insomnia PBPA Category and 30 Day Notice to Prior Authorize Zolpimist[®] – See Appendix F.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman

9. **Action Item – Annual Review of Glaucoma PBPA Category – See Appendix G.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

10. **Utilization Review of Anti-Migraine Products – See Appendix H.**
 - A. Product Overview
 - B. Current Restrictions
 - C. Utilization Review
 - D. COP Recommendations

Items to be presented by Dr. Keast, Dr. McNeill, Chairman

11. **Utilization Report for Second Quarter Fiscal Year 2009 – See Appendix I.**
 - A. Top 25 Sub-Therapeutic Classes by Total Reimbursement
 - B. Top 10 Sub-Therapeutic Classes with Top 5 Products by Total Reimbursement
 - C. Top 25 Drugs by Total Reimbursement

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**
 - A. Utilization Review of Fibromyalgia
 - B. Utilization Review of Otic Antibiotics
 - C. Utilization Review of Antiemetics
 - D. New Product Reviews

14. **Adjournment**